MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) will present five research posters at the 67th American Academy of Neurology (AAN) Annual Meeting (April 18-25, Washington, D.C.), including findings from two pooled Phase 3 studies (Studies 093-045 and 093-046) evaluating the safety and efficacy of Aptiom® (eslicarbazepine acetate) as a potential monotherapy treatment of partial-onset seizures. Sunovion’s supplemental New Drug Application (sNDA) for the use of APTIOM as monotherapy for partial-onset seizures is currently under review by the U.S. Food and Drug Administration (FDA).
Help employers find you! Check out all the jobs and post your resume.
